Literature DB >> 32544805

Magnetic resonance imaging/transrectal ultrasonography fusion guided seed placement in a phantom: Accuracy between 2-seed versus 1-seed strategies.

Qian Li1, Yu Duan2, Masoud Baikpour3, Theodore T Pierce3, Colin J McCarthy4, Ashraf Thabet3, Suk-Tak Chan5, Anthony E Samir6.   

Abstract

PURPOSE: To investigate whether the 2-seed placement per Magnetic Resonance Imaging (MRI) suspicious lesion yields a higher seed placement accuracy than a 1-seed strategy on a phantom.
METHODS: Eight olives embedded in gelatin, each simulating a prostate, underwent MRI. Three virtual spherical lesions (3, 5, and 8 mm diameters) were marked in each olive on the MRI images and co-registered to the MRI/Transrectal Ultrasonography (TRUS) fusion biopsy system. Two radiologists placed 0.5 mm fiducials, targeting the center of each virtual lesion under fusion image guidance. Half of the 8 olives in each phantom were assigned either to the 1-seed or 2-seeds per lesion strategy. Post-procedure Computed Tomography (CT) images identified each seed and were fused with MR to localize each virtual lesion and collected the seed placement error - distance between the virtual target and the corresponding seed (using the closer seed for the 2-seed strategy). Seed placement success is defined as fiducial placement within a lesion boundary.
RESULTS: Each operator repeated the procedure on three different phantoms, and data from 209 seeds placed for 137 lesions were analyzed, with an overall error of 3.03 ± 1.52 mm. The operator skill, operator phantom procedural experience, lesion size, and number of seeds, were independently associated with the seed placement error. Seed placement success rate was higher for the 2-seed group compared to 1-seed, although the difference was not statistically significant.
CONCLUSIONS: Placing 2 seeds per MRI lesion yielded a significantly lower error compared to 1-seed strategy, although seed placement success rate was not significantly different.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Magnetic resonance imaging; Phantom; Prostate cancer; Ultrasound fusion biopsy

Mesh:

Year:  2020        PMID: 32544805      PMCID: PMC7657060          DOI: 10.1016/j.ejrad.2020.109126

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  24 in total

1.  3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion.

Authors:  Osamu Ukimura; Mihir M Desai; Suzanne Palmer; Samuel Valencerina; Mitchell Gross; Andre L Abreu; Monish Aron; Inderbir S Gill
Journal:  J Urol       Date:  2012-01-21       Impact factor: 7.450

2.  Phantom study of a novel stereotactic prostate biopsy system integrating preinterventional magnetic resonance imaging and live ultrasonography fusion.

Authors:  Timur H Kuru; Matthias Roethke; Valentin Popeneciu; Dogu Teber; Sascha Pahernik; Pawel Zogal; Heinz-Peter Schlemmer; Boris A Hadaschik; Markus Hohenfellner
Journal:  J Endourol       Date:  2012-03-19       Impact factor: 2.942

3.  An Ex Vivo Phantom Validation Study of an MRI-Transrectal Ultrasound Fusion Device for Targeted Prostate Biopsy.

Authors:  Olivier Wegelin; Kirsten R Henken; Diederik M Somford; Frans A M Breuking; Ruud J Bosch; Christiaan F P van Swol; Harm H E van Melick
Journal:  J Endourol       Date:  2016-03-16       Impact factor: 2.942

4.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

5.  Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?

Authors:  L Schimmöller; M Quentin; D Blondin; F Dietzel; A Hiester; C Schleich; C Thomas; R Rabenalt; H E Gabbert; P Albers; G Antoch; C Arsov
Journal:  Eur Radiol       Date:  2016-02-26       Impact factor: 5.315

6.  Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence.

Authors:  Niall M Corcoran; Matthew K H Hong; Rowan G Casey; Antonio Hurtado-Coll; Justin Peters; Laurence Harewood; S Larry Goldenberg; Chris M Hovens; Anthony J Costello; Martin E Gleave
Journal:  BJU Int       Date:  2011-03-28       Impact factor: 5.588

7.  Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12-Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients.

Authors:  Chinonyerem Okoro; Arvin K George; M Minhaj Siddiqui; Soroush Rais-Bahrami; Annerleim Walton-Diaz; Nabeel A Shakir; Jason T Rothwax; Dima Raskolnikov; Lambros Stamatakis; Daniel Su; Baris Turkbey; Peter L Choyke; Maria J Merino; Howard L Parnes; Bradford J Wood; Peter A Pinto
Journal:  J Endourol       Date:  2015-07-23       Impact factor: 2.942

8.  The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer.

Authors:  Alexandre Fourcade; Charlotte Payrard; Valentin Tissot; Marie-Aimée Perrouin-Verbe; Nicolas Demany; Sophie Serey-Effeil; Pierre Callerot; Jean-Baptiste Coquet; Laurent Doucet; Charles Deruelle; Vincent Joulin; Michel Nonent; Georges Fournier; Antoine Valeri
Journal:  Scand J Urol       Date:  2018-02-20       Impact factor: 1.612

9.  Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.

Authors:  Pietro Pepe; Antonio Garufi; Gian Domenico Priolo; Antonio Galia; Filippo Fraggetta; Michele Pennisi
Journal:  J Urol       Date:  2018-04-19       Impact factor: 7.450

10.  Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology-Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?

Authors:  Brian P Calio; Abhinav Sidana; Dordaneh Sugano; Sonia Gaur; Mahir Maruf; Amit L Jain; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto; Baris Turkbey
Journal:  J Urol       Date:  2018-01-20       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.